ArticleChinese medicine2025
Cyclovirobuxine D ameliorates cardiomyocyte senescence in diabetic cardiomyopathy mice by enhancing mitochondrial function via sirtuin 3-ATP5O signal axis.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting SIRT3 in Diabetic Cardiomyopathy: Mechanism-Based Therapeutic Strategies.Cardiovascular drugs and therapy · 2026Review
- Cellular Senescence in Diabetic Cardiomyopathy: Mechanistic Insights and Therapeutic Perspectives.Cardiovascular drugs and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundDiabetic cardiomyopathy (DCM) is a cardiovascular complication, with cardiomyocyte senescence being a key pathological process. Cyclovirobuxine D (CVB-D), the active compound in Buxus sinica (Rehd. et Wils.) var. parvifolia M. Cheng. CVB-D has potentially promising diabetes-related cardiomyocyte senescence-mitigating effects. Nevertheless, the impact of CVB-D on inhibiting cardiomyocyte senescence has not been widely investigated and molecular mechanisms remain ambiguous.
methodsA diabetic mouse model was established via a high-fat diet (HFD) combined with streptozotocin (STZ). Sirtuin 3 (SIRT3) knockout, SIRT3 overexpression, and ATP5O knockout mouse models were constructed through 4-week intravenous injections of AAV9-U6-SIRT3, AAV9-CMV-SIRT3, AAV9-U6-ATP5O, and their negative controls (AAV9-CMV-NC and AAV9-U6-NC). A primary mice cardiomyocytes (NMVMs) senescence model was developed using high palmitic acid and high glucose (PA/HG). Western blotting, reverse transcription-quantitative PCR (qRT-PCR), immunofluorescence, β-galactosidase staining and flow cytometry were performed to determine the protective role of CVB-D against cardiomyocyte senescence. The underlying mechanisms of CVB-D were investigated via molecular docking, coimmunoprecipitation (Co-IP), microscale thermophoresis (MST), surface plasmon resonance (SPR) binding assay, isothermal titration calorimetry (ITC) and LC-MS/MS analysis.
resultsCVB-D treatment improves mitochondrial dysfunction in DCM and thus alleviates the aging of cardiomyocytes in vitro and in vivo. And then, the results revealed that CVB-D can upregulate the acetylation level of ATP5O by upregulating the expression of SIRT3 to alleviate cardiomyocyte senescence. The results of Co-IP, MST, SPR, and ITC, among other experiments revealed that CVB-D plays a functional role through the SIRT3-ATP5O axis. Potential ATP5O acetylation sites by the LC-MS/MS analysis, we found that SIRT3 deacetylates the K162 site of ATP5O in primary mouse cardiomyocytes. Furthermore, transfection with a deacetylated or acetylated mimic plasmid containing ATP5O decreased or promoted mitochondrial damage, respectively. SIRT3 overexpression ameliorated DCM, whereas ATP5O knockout inhibited the protective effects of SIRT3 overexpression.
conclusionIt is the first time that we confirm CVB-D ameliorating cardiomyocyte senescence in DCM by enhancing mitochondria dysfunction through activated SIRT3-ATP5O axis. It also suggests that CVB-D could be employed in the future to treat cardiomyocyte senescence caused by DCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.